Table 2.
Response and transplant-related toxicity
| Variable | Overall | Upfront-allo | Auto-allo | Relapse | P | Missing |
|---|---|---|---|---|---|---|
| N (%) | 205 (100) | 75 (37) | 74 (36) | 56 (27) | ||
| Median engraftmenta, days (range) | 17 (1–59) | 16 (1–31) | 17 (1–47) | 17 (1–59) | 0.390 | |
| Overall response rate (≥ PR) | 177 (86) | 68 (91) | 67 (91) | 42 (75) | 0.012 | 3 (1) |
| Best response after allo-SCT | 0.072 | 3 (1) | ||||
| sCR | 26 (13) | 11 (15) | 13 (18) | 2 (4) | ||
| CR | 77 (38) | 30 (40) | 32 (43) | 15 (27) | ||
| VGPR | 49 (24) | 19 (25) | 15 (20) | 15 (27) | ||
| PR | 25 (12) | 8 (11) | 7 (9) | 10 (18) | ||
| MR | 2 (1) | 1 (1) | 0 (0) | 1 (2) | ||
| SD | 3 (1) | 0 (0) | 1 (1) | 2 (4) | ||
| PD | 20 (10) | 5 (7) | 5 (7) | 10 (18) | ||
| aGVHD grades 2–4b (%, 95% CI) | 24% (18–30%) | 21% (12–31%) | 31% (20–42%) | 20% (9–30%) | 0.330 | |
| 2 | 12% (7–16%) | 8% (2–14%) | 15% (7–23%) | 13% (4–21%) | 0.431 | |
| 3 | 10% (6–14%) | 13% (6–21%) | 11% (4–18%) | 5% (0–11%) | 0.369 | |
| 4 | 2% (0–5%) | 0 | 5% (0–11%) | 2% (0–5%) | 0.094 | |
| cGVHD at 5 years (%, 95% CI) | 62% (55–69%) | 58% (46–69%) | 74% (64–84%) | 52% (38–65%) | 0.008 | |
| ext. cGVHD at 5 years (%, 95% CI) | 47% (40–54%) | 41% (30–53%) | 58% (47–69%) | 39% (26–52%) | 0.031 |
aDefined as the first of three consecutive days with an absolute neutrophil count > 0.5 × 109/l. Two engraftment failures, 1 due to PD and one due to early death
bCumulative incidence at 100 days post-transplant
Upfront-allo allo-SCT performed first line without a previous auto-SCT, auto-allo allo-SCT performed after auto-SCT in first line, relapse allo-SCT performed after relapse, allo-SCT allogeneic hematopoietic stem cell transplantation, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progressive disease, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, ext. cGVHD extensive chronic graft-versus-host disease